GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

NP10679   Click here for help

GtoPdb Ligand ID: 13847

Synonyms: NP-10679
Approved drug
NP10679 is an approved drug
Compound class: Synthetic organic
Comment: NP10679 is an orally bioavailable,brain penetrant GluN2B-selective NMDA receptor inhibitor [1-2]. It offers potential to reduce acute brain injury (subsequent to ischemic stroke or aneurysmal subarachnoid hemorrhage) and for treatment of neuropsychiatric indications [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 65.04
Molecular weight 449.47
XLogP 1.38
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CC(=O)NC2=CC=C(C=C12)OC[C@@H](CN3CCN(CC3)C4=CC=C(C=C4)C(F)(F)F)O
Isomeric SMILES C1CC(=O)NC2=C1C=C(C=C2)OC[C@@H](CN3CCN(CC3)C4=CC=C(C=C4)C(F)(F)F)O
InChI InChI=1S/C23H26F3N3O3/c24-23(25,26)17-2-4-18(5-3-17)29-11-9-28(10-12-29)14-19(30)15-32-20-6-7-21-16(13-20)1-8-22(31)27-21/h2-7,13,19,30H,1,8-12,14-15H2,(H,27,31)/t19-/m1/s1
InChI Key QJKYLYXHWSCZQT-LJQANCHMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
NP10679 is a clinical candidate as a novel neuroprotective agent.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03565861 Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers Phase 1 Interventional Neurop Inc.
NCT04007263 A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers Phase 1 Interventional Neurop Inc. 3